Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital
March 15, 2019 6:51 AM EDTBMO Capital analyst Gary Nachman lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $21.00 (from $24.00) while maintaining a Outperform rating following relatively in-line 4Q18 results.
guidance is appropriately conservative and should be very achievablemanagement sounded confident in several potential nondilutive financing options... More
Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Below Guidance
March 14, 2019 7:12 AM EDTAquestive Therapeutics Inc. (NASDAQ: AQST) reported Q4 EPS of ($0.56), $0.05 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.69 million.
"Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a... More
